BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jalkh G, Abi Nahed R, Macaron G, Rensel M. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis. Vaccines (Basel) 2020;9:12. [PMID: 33375365 DOI: 10.3390/vaccines9010012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wu H, Ward M, Brown A, Blackwell E, Umer A. COVID-19 Vaccine intent in appalachian patients with multiple sclerosis. Mult Scler Relat Disord 2021;57:103450. [PMID: 34911005 DOI: 10.1016/j.msard.2021.103450] [Reference Citation Analysis]
2 Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. PPA 2022;Volume 16:1307-19. [DOI: 10.2147/ppa.s221882] [Reference Citation Analysis]
3 Shafin N, Ismail CAN, Mustafa MZ, Ghani N, Ahmad AH, Othman Z, Wijaya A, Zakaria R. Thematic analysis of multiple sclerosis research by enhanced strategic diagram. Mult Scler 2022;:13524585221075542. [PMID: 35164590 DOI: 10.1177/13524585221075542] [Reference Citation Analysis]
4 Rubino V, Palatucci AT, La Rosa G, Giovazzino A, Aruta F, Damiano S, Carriero F, Santillo M, Iodice R, Mondola P, Ruggiero G, Terrazzano G. Superoxide Dismutase-1 Intracellular Content in T Lymphocytes Associates with Increased Regulatory T Cell Level in Multiple Sclerosis Subjects Undergoing Immune-Modulating Treatment. Antioxidants (Basel) 2021;10:1940. [PMID: 34943042 DOI: 10.3390/antiox10121940] [Reference Citation Analysis]
5 Mirabella M, Annovazzi P, Brownlee W, Cohen JA, Kleinschnitz C, Wolf C. Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate? Front Neurol 2022;13:844873. [DOI: 10.3389/fneur.2022.844873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]